Products for Research Use Only

Guanfacine

CAT: 0804-HY-17416A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17416A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD) [1][2][3].
CAS Number
29110-47-2
UNSPSC
12352005
Hazard Statement
H301, H311, H331
Target
Adrenergic Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Neurological Disease; Endocrinology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/guanfacine.html
Concentration
10mM
Purity
99.85
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(NC(N)=N)CC1=C(Cl)C=CC=C1Cl
Molecular Formula
C9H9Cl2N3O
Molecular Weight
246.09
Precautions
H301, H311, H331
References & Citations
[1]Amy F T Arnsten, et al. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012 Mar;85 (1) :45-58. Epub 2012 Mar 29.|[2]P. A. Van Zwieten, et al. The pharmacology of centrally acting antihypertensive drugs. Br J Clin Pharmacol. 1983; 15 (Suppl 4) : 455S–462S. |[3]Min Wang, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007 Apr 20;129 (2) :397-410.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
α adrenergic receptor
Citation 01
Nat Commun. 2025 May 16;16 (1) :4560.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Patent. US20230147129A1.